INTRODUCTION
The most commonly used form of therapy in healthcare facilities is infusion therapy [1] , which implies that drug delivery is a critical aspect in health safety. Because of the widespread application by many users in critical health situations, infusion errors are often made, with potential dramatic effects in the patients. There are various examples where adverse incidents, morbidity and mortality, can be traced back to poor drug delivery, e.g, Snijder et al [2] published a review in which medical errors associated with flow rate variability in infusion devices are described, where they emphasized the severe and lasting health damage that has occurred A well-defined metrological infrastructure is needed to allow infusion pump manufacturers to include robust information on the real dose delivered to the patient, and drug delivery devices operators to have a better metrological knowledge of these critical devices, thus preventing incorrect measurement results and significantly improving patient safety.
Metrology can bridge the knowledge gap by designing a representative multi-infusion intravenous system for testing how different liquids mix and how this affects drug concentration. The increasing implementations of novel microfluidic solutions in healthcare urge the development of a metrological infrastructure for validating quality and reproducibility. The overall aim of this project is to improve dosing accuracy and enable traceable measurements of volume, flow and pressure of existing drug delivery devices and inline sensors operating at very low flow rates (lower than 100 nL/min). This can be achieved through the development of new calibration methods and improved metrological infrastructures. Another goal of this project is to investigate the influence of (a) different regimes of flow rate, (b) physical properties of delivered fluids (e.g., viscoelasticity), and (c) occlusion phenomena in multi-infusion systems. This knowledge will help in preventing inaccurate measurement results and thus improve patient safety.
II. STATE OF THE ART AND PROGRESS BEYOND IT
In 2004, in a metrological effort to understand and improve multi-infusion, Clark [3] defined the crucial performance aspect of an infusion system and established the importance of a patient receiving the right dose of the required substances in a given time. However, in multiinfusion, this is not an easy task. The first steps towards a better knowledge of the real flow rates and concentration of the drugs that are delivered to the patients' blood stream were made in previous projects [4, 5] .
In MeDD I (Metrology for Drug Delivery I) [4] the aim was to prevent errors by upgrading calibration services and improving knowledge transfer to the end-user [4] . The infrastructure, consisting of traceable calibration services for drug delivery systems for flow rates down to 100 nL/min was developed in five European National Metrology Institutes (NMIs) [6, 7] . Syringe pumps and peristaltic pumps with accessories were tested [8] . The effects of variations in several physical parameters in infusion systems were incorporated in a predictive model [9] .
This new project will go beyond the research conducted in MeDD I [4] by investigating the influence of fast changing flow rates due to a change in the pre-set flow rate. Also, a multi-infusion setup will be developed to investigate fluid flow rates and fluid compositions in the outlet of the infusion line. This setup will allow the assessment of the performance of drug delivery devices in multi-infusion systems and the determination of the concentration of each drug being administered.
III. SCIENTIF OBJECTIVES
This project is coordinated by IPQ, the Portuguese Institute of Quality and has the overall goal of enabling traceable measurements of volume, flow and pressure of existing drug delivery devices (and other medical devices, like infusion pumps analysers) and inline sensors that work at a flow rate lower than 100 nL/min, in order to prevent inaccurate measurement results. This project will also investigate different flow rate regimes, liquid mixing behaviour and occlusion phenomena in multi-infusion systems with the purpose of improving dosing accuracy in each infusion line.
The specific objectives of the project are:
1.
To develop new traceable techniques for generating and measuring the response or delay time regarding changes in flow rate, in the flow range from 5 nL/min to 100 nL/min, using Newtonian liquids.
2. To upgrade the existing flow facilities and knowledge of the participant NMIs in order to enable traceable inline measurement of the dynamic viscosity of Newtonian liquids, as a function of the flow rate and pressure difference, with a target uncertainty value of 2 % (k=2).
3. To develop and validate novel calibration procedures for existing drug delivery devices (e.g. infusion pumps, pain controllers and infusion pump analyzers) with traceability to a primary standard and with a target uncertainty value of 2 % for a range of 5 nL/min up to 600 mL/min and in addition to develop a proof-of-concept of an on-chip microfluidic pump used as transfer standard in drug discovery and organ-on-a-chip applications for flow rates from 5 nL/min to 100 nL/min. 4. To design and develop a multi infusion system containing check valves, with several options for testing how liquids, with different viscosities mix and flow and how this affects drug concentration.
5. To facilitate the take up of the technology and measurement infrastructure developed in the project by the measurement supply chain (i.e. accredited laboratories, instrumentation manufacturers, etc.), standards developing organizations and end-users (i.e. hospitals and health centers).
IV. IMPACT

A. On society and health sectors
The main goal of this project is to improve diagnostics, patient treatment and patient safety by developing new calibration methods. This results in adequate traceability for flow rate measurements performed by several drug delivery devices such as multi infusion systems, insulin pumps and pain controllers working at flow rates as low as 100 nL/min.
It is known that drug errors account for a significant percentage of medical errors, with dosing errors being a significant subset of them [10] [11] [12] [13] . Depending on the drug type, the patient characteristics and the applied therapy, dosing errors can have severe consequences, including a substantial number of fatalities.
A better understanding of how dosing errors can occur, and how to increase the accuracy of the drug delivery devices will have a noticeable impact on the health industry and significantly improve patient treatment and safety. Therefore, any attempt to prevent adverse events by improving the knowledge on actual doses can already make an enormous difference for the individual patient, especially new born babies, and have a significant impact on the health sector as a whole. As medication and dosing errors occur frequently, a considerable impact on society through improved patient safety can be expected by improving the calibration and administration conditions for drug delivery devices and setups. Important examples can be found in chemotherapy in oncology, in anaesthesia, in the operating theatre and in nursery wards, especially for the neonates. The calibration methods are also important in drug injection applications in very small anatomic regions of the body, for example in the inner ear. Improving metrology for microfluidic methods in this field could help to find new horizons for the treatment of acute deafness and Meniere's disease.
Furthermore, occlusion alarm quality can be improved, and occlusion alarm fatigue diminished by more reliable pressure measurements.
Accurate drug delivery will also have economic benefits. In modern medicine, many sophisticated pharmaceuticals are available, but only at high prices. Metrology can help prevent waste of expensive medication, by enabling the delivery of accurate dosage.
Finally, the infusion pumps analysers used by maintenance hospitals need traceability to primary reference, which is something, that unfortunately is still not common these days, but for critical patient care, hospitals with ISO 9001 accreditation need traceable calibrated devices, as it is required by the relevant standard.
B. On metrology
This project will upgrade various existing facilities for flow measurements from 5 nL/min up to 100 nL/min using different Newtonian fluids as test medium. These new facilities will be validated by means of an inter-comparison with stable transfer standards allowing new measurement capabilities.
New calibration methods will be developed based on optical methods and this knowledge will be disseminated across the scientific community by relevant publications in scientific journals and congresses.
These new calibration methods will be beneficial for both accredited laboratories and manufacturers of drug delivery devices. These novel procedures can later be updated for microfluidic devices used in health, mainly in organ-on-achip technology. A calibration guide for the different type of drug delivery devices will be drafted describing the calibration methods, conditions under which they are to be operated, target uncertainty and best working practices. The draft will be submitted to EURAMET and made available to end users.
C. On standardisation
In this project, procedures and methods for the calibration of drug delivery devices already on the market are going to be developed. This information will be supplied to the relevant ISO technical committees (TC). For example, the current version of IEC 60601-2-24 used by manufacturers to develop drug delivery devices and by laboratories and maintenance departments of hospitals to verify and calibrate drug delivery devices is roughly 20 years old and is outdated. Moreover, the given measurement methods are not suitable for very low flow rates (< 100 nL/min) relevant to implantable infusion pumps where applications are encountered.
An urging need to update the measurement procedures for different types of pumps and master calibrators is widely accepted. It is envisaged that the project will impact on Section Eight of IEC 60601-2-24 (Accuracy of operating data and protection against hazardous output).
This project can also supply inputs on the Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017 on medical devices that are currently lacking information regarding maximum permissible errors of several medical devices, including drug delivery devices.
V. THE ROLE OF IPQ
IPQ is the coordinator of this project; it is also the work package leader of Impact (WP5).
At IPQ, in 2012, a microflow setup was developed comprising two different assemblies depending on the measurement range. In this two assemblies different scales are used, namely an AX 26 mass comparator of 0,001 mg resolution and 20 g maximum capacity and a XP 2015 balance with 0,01 mg resolution and 220 g maximum capacity (Figure 1) . In both assemblies the mass and time data are collected and treated using an application developed in Labview software, and an evaporation trap is used in the AX26 balance assembly to minimize evaporation. These assemblies are used to calibrate flow meters and flow generators such as syringe pumps for flow rates down to 120 L/h. Within this project IPQ will develop an optical method in order to expand the minimum range to 5 nL/min. IPQ will also have an active participation in the development of new calibration procedures for existing drug delivery devices and in cooperation with INESC (Institute for Systems Engineering and Computers) will develop a microfluidic pump. 
VI. CONCLUSIONS
By improving the instruments accuracy, which will reduce dosing errors, lives can be saved. This can be achieved by wider uptake of traceable calibrations of low and ultra-low flow infusion (master) devices and by improved knowledge of calibrating drug delivery devices in clinical environments, especially in the case of multiple infusion systems. This project directly benefits the general community because it allows identifying and reducing dosing errors in drug delivery devices used for patient treatment and diagnostic.
